Cephasonics' cQuest Cicada Ultrasound Subsystem Earns CE Mark.
M2 PHARMA-November 12, 2015-Cephasonics' cQuest Cicada Ultrasound Subsystem Earns CE Mark
(C)2015 M2 COMMUNICATIONS
- US-based open embedded-ultrasound platform specialist Cephasonics has received CE mark approval for its cQuest Cicada subsystem, a 64-channel ultrasound front-end with AutoFocus beamforming technology, the company said on Thursday.
CE marking indicates compliance with European Union regulations governing medical devices, no matter where in the world they are manufactured, and enables free movement within the European market.
The cQuest Cicada product line is a scalable, full-featured ultrasound platform that offers a high level of flexibility and excellent image quality, enabling fast time to market for customers' end products.
This line begins with a 64-channel cQEngine hardware platform that is expandable to 256 channels.
Cephasonics is a medical- and industrial-device technology firm utilising ultrasound and the power of the cloud to bring about the ubiquitous adoption of ultrasound-based measurement products that improve the quality of life.
Launched with a management buyout in March 2012 and headquartered in Santa Clara, Calif., Cephasonics' ultrasound technology, including its AutoFocus beamforming technology, has won multiple industry awards for innovation.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 12, 2015|
|Previous Article:||New Intermountain Healthcare, Velano Vascular Partnership to Study Inpatient Blood Draw Procedures.|
|Next Article:||Janssen Launches New Platform for Improving Monitoring in Inflammatory Bowel Diseases.|